Clinical Performance of the BD CTGCTV2 Assay for the BD MAX System for Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis Infections.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
25
5
2021
Statut:
ppublish
Résumé
Diagnostic options to combat the increasing rates of sexually transmitted infections recorded throughout the world increasingly include multiplex assays. Here we describe the estimated sensitivity and specificity of a triplex molecular assay that simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (or gonococci [GC]), and Trichomonas vaginalis (TV). Participants (2547 women and 1159 men) were recruited from 12 clinics in the United States. BD CTGCTV2 for BD MAX System assay (CTGCTV2) results were obtained from vaginal and endocervical swabs, endocervical samples in cytology medium, and female and male urine. Results were compared with infection standards that were sample type and pathogen dependent. Female specimen sensitivity estimates ranged from 92.7% to 98.4%, 92.9% to 100%, and 86.6% to 100% for CT, GC and TV, respectively. Male urine sensitivity estimates were 96.7%, 99.2%, and 97.9% for CT, GC, and TV, respectively. Specificity estimates were >98.7% for all sample types. BD CTGCTV2 performed well using a variety of sample types. As a true triplex assay, performed using a benchtop instrument, BD CTGCTV2 may be useful in settings where no testing is currently performed and in settings, such as reference laboratories, where testing turnaround time may be several days. Use of this assay at local laboratories may result in greater access to testing and a shorter time to result, which are important steps for improving our ability to combat sexually transmitted infections.
Sections du résumé
BACKGROUND
Diagnostic options to combat the increasing rates of sexually transmitted infections recorded throughout the world increasingly include multiplex assays. Here we describe the estimated sensitivity and specificity of a triplex molecular assay that simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (or gonococci [GC]), and Trichomonas vaginalis (TV).
METHODS
Participants (2547 women and 1159 men) were recruited from 12 clinics in the United States. BD CTGCTV2 for BD MAX System assay (CTGCTV2) results were obtained from vaginal and endocervical swabs, endocervical samples in cytology medium, and female and male urine. Results were compared with infection standards that were sample type and pathogen dependent.
RESULTS
Female specimen sensitivity estimates ranged from 92.7% to 98.4%, 92.9% to 100%, and 86.6% to 100% for CT, GC and TV, respectively. Male urine sensitivity estimates were 96.7%, 99.2%, and 97.9% for CT, GC, and TV, respectively. Specificity estimates were >98.7% for all sample types.
CONCLUSIONS
BD CTGCTV2 performed well using a variety of sample types. As a true triplex assay, performed using a benchtop instrument, BD CTGCTV2 may be useful in settings where no testing is currently performed and in settings, such as reference laboratories, where testing turnaround time may be several days. Use of this assay at local laboratories may result in greater access to testing and a shorter time to result, which are important steps for improving our ability to combat sexually transmitted infections.
Identifiants
pubmed: 33448727
doi: 10.1097/OLQ.0000000000001280
pii: 00007435-202102000-00010
pmc: PMC7817187
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-140Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Sexually Transmitted Diseases Association.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: B.V.D.P. received institutional research support, honorarium, or consulting fees from Becton, Dickinson and Company; Atlas Genetics; Beckman Coulter; Click Diagnostics; Hologic; Luminex; Roche; and SpeeDx. C.A.G. received institutional research support, honorarium, or consulting fees from Becton, Dickinson and Company; Atlas Genetics; Beckman Coulter; Click Diagnostics; Hologic; Quidel; and SpeeDx. E.T.-C., S.K., and C.K.C. are employees of the study sponsor. T.E.D., K.H.F., S.N.T., and M.H.A. have no conflicts of interest.
Références
World Health Organization (WHO). Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections—2008. Geneva, Switzerland: World Health Organization, 2012.
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. Atlanta, GA: Department of Health and Human Services:2019.
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2017. Atlanta, GA: Department of Health and Human Services:2018.
Flagg EW, Meites E, Phillips C, et al. Prevalence of Trichomonas vaginalis among civilian, noninstitutionalized male and female population aged 14 to 59 years: United States, 2013 to 2016. Sex Transm Dis 2019; 46:e93–e96.
Gratrix J, Plitt S, Turnbull L, et al. Trichomonas vaginalis prevalence and correlates in women and men attending STI clinics in Western Canada. Sex Transm Dis 2017; 44:627–629.
Plitt SS, Garfein RS, Gaydos CA, et al. Prevalence and correlates of Chlamydia trachomatis , Neisseria gonorrhoeae , Trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis 2005; 32:446–453.
Meites E, Gaydos CA, Hobbs MM, et al. A review of evidence-based care of symptomatic trichomoniasis and asymptomatic Trichomonas vaginalis infections. Clin Infect Dis 2015; 61(Suppl 8):S837–S848.
Sena AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007; 44:13–22.
Trent M, Ellen JM, Frick KD. Estimating the direct costs of pelvic inflammatory disease in adolescents: A within-system analysis. Sex Transm Dis 2011; 38:326–328.
Chesson HW, Kirkcaldy RD, Gift TL, et al. An illustration of the potential health and economic benefits of combating antibiotic-resistant gonorrhea. Sex Transm Dis 2018; 45:250–253.
Owusu-Edusei K Jr., Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40:197–201.
Kissinger P. Trichomonas vaginalis : A review of epidemiologic, clinical and treatment issues. BMC Infect Dis 2015; 15:307.
Das BB, Ronda J, Trent M. Pelvic inflammatory disease: Improving awareness, prevention, and treatment. Infect Drug Resist 2016; 9:191–197.
Tsevat DG, Wiesenfeld HC, Parks C, et al. Sexually transmitted diseases and infertility. Am J Obstet Gynecol 2017; 216:1–9.
Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: A systematic review and meta-analysis. Sex Transm Dis 2014; 41:369–376.
Olson-Chen C, Balaram K, Hackney DN. Chlamydia trachomatis and adverse pregnancy outcomes: Meta-analysis of patients with and without infection. Matern Child Health J 2018; 22:812–821.
Waight MT, Rahman MM, Soto P, et al. Sexually transmitted diseases during pregnancy in Louisiana, 2007–2009: High-risk populations and adverse newborn outcomes. J La State Med Soc 2013; 165:219–226.
LeFevre ML; U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 161:902–910.
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-03):1–137.
Van Der Pol B, Williams JA, Fuller D, et al. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. J Clin Microbiol 2016; 55:155–164.
Van Der Pol B. Profile of the triplex assay for detection of chlamydia, gonorrhea and trichomonas using the BD MAX system. Expert Rev Mol Diagn 2017; 17:539–547.
Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. BMJ Open 2016; 6:e012799.
BD CTGCTV2 for MAX™ System Assay [Package Insert]. Sparks-Glencoe, MD: Becton, Dickinson and Company, 2020.
Wenzel D, Zapf A. Difference of two dependent sensitivities and specificities: Comparison of various approaches. Biom J 2013; 55:705–718.
Kim HY. Statistical notes for clinical researchers: chi-squared test and Fisher's exact test. Restor Dent Endod 2017; 42:152–155.
Papp J, Schachter J, Gaydos C, et al. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae —2014. MMWR 2014; 63(RR-2):1–24.
Van Der Pol B, Taylor SN, Liesenfeld O, et al. Vaginal swabs are the optimal specimen for detection of genital Chlamydia trachomatis or Neisseria gonorrhoeae using the Cobas 4800 CT/NG test. Sex Transm Dis 2013; 40:247–250.
Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/NG Xpert rapid PCR test for detection of Chlamydia trachomatis and Neisseria gonorrhoeae . J Clin Microbiol 2013; 51:1666–1672.
Gaydos CA, Cartwright CP, Colaninno P, et al. Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeae . J Clin Microbiol 2010; 48:3236–3243.
Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae : Results from a multicenter evaluation of the APTIMA assays for both infections. Sex Transm Dis 2005; 32:725–728.
Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012; 50:2601–2608.